Do analysts prefer CARA or FRX?

Given Cara Operations' higher possible upside, research analysts clearly believe Cara Operations is more favorable than Fennec Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cara Operations 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Fennec Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00

Which has higher valuation & earnings, CARA or FRX?

Cara Operations has higher earnings, but lower revenue than Fennec Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cara Operations N/A N/A N/A N/A N/A Fennec Pharmaceuticals C$51.00M 8.45 -C$800.44K -C$0.29 N/A

Do analysts rate FRX or CRON?

Cronos Group has a consensus target price of C$4.75, indicating a potential upside of 26.33%. Given Cronos Group's higher probable upside, analysts plainly believe Cronos Group is more favorable than Fennec Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Fennec Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00 Cronos Group 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00

Which has stronger valuation and earnings, FRX or CRON?

Fennec Pharmaceuticals has higher earnings, but lower revenue than Cronos Group. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Fennec Pharmaceuticals C$51.00M 8.45 -C$800.44K -C$0.29 N/A Cronos Group C$159.54M 8.81 -C$32.78M N/A N/A

Do analysts prefer TLRY or FRX?

Tilray Brands presently has a consensus target price of C$13.30, suggesting a potential upside of 91.09%. Given Tilray Brands' higher possible upside, analysts plainly believe Tilray Brands is more favorable than Fennec Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tilray Brands 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Fennec Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00

Does the media prefer TLRY or FRX?

In the previous week, Fennec Pharmaceuticals had 2 more articles in the media than Tilray Brands. MarketBeat recorded 4 mentions for Fennec Pharmaceuticals and 2 mentions for Tilray Brands. Fennec Pharmaceuticals' average media sentiment score of 0.20 beat Tilray Brands' score of 0.07 indicating that Fennec Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tilray Brands 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Fennec Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate FRX or ITH?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Fennec Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00 International Tower Hill Mines 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts prefer TEV or FRX?

Given Tervita's higher possible upside, equities research analysts plainly believe Tervita is more favorable than Fennec Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tervita 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Fennec Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00

Fennec Pharmaceuticals (FRX) Competitors

C$12.40 0.00 (0.00%)

As of 06/12/2026

Compare

FRX vs. CARA, CRON, TLRY, ITH, and TEV

Should you buy Fennec Pharmaceuticals stock or one of its competitors? MarketBeat compares Fennec Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Fennec Pharmaceuticals include Cara Operations (CARA), Cronos Group (CRON), Tilray Brands (TLRY), International Tower Hill Mines (ITH), and Tervita (TEV). These companies are all part of the "pharmaceutical products" industry.

How does Fennec Pharmaceuticals compare to Cara Operations?

Cara Operations (TSE:CARA) and Fennec Pharmaceuticals (TSE:FRX) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, dividends, risk and media sentiment.

Cara Operations has higher earnings, but lower revenue than Fennec Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cara Operations	N/A	N/A	N/A	N/A	N/A
Fennec Pharmaceuticals	C$51.00M	8.45	-C$800.44K	-C$0.29	N/A

12.7% of Fennec Pharmaceuticals shares are held by institutional investors. 16.2% of Fennec Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Cara Operations has a net margin of 0.00% compared to Fennec Pharmaceuticals' net margin of -17.22%. Cara Operations' return on equity of 0.00% beat Fennec Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cara Operations	N/A	N/A	N/A
Fennec Pharmaceuticals	-17.22%	-58.09%	8.88%

In the previous week, Fennec Pharmaceuticals had 4 more articles in the media than Cara Operations. MarketBeat recorded 4 mentions for Fennec Pharmaceuticals and 0 mentions for Cara Operations. Fennec Pharmaceuticals' average media sentiment score of 0.20 beat Cara Operations' score of 0.00 indicating that Fennec Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Cara Operations	Neutral
Fennec Pharmaceuticals	Neutral

Given Cara Operations' higher possible upside, research analysts clearly believe Cara Operations is more favorable than Fennec Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cara Operations	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Fennec Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	4.00

Summary

Fennec Pharmaceuticals beats Cara Operations on 8 of the 11 factors compared between the two stocks.

How does Fennec Pharmaceuticals compare to Cronos Group?

Fennec Pharmaceuticals (TSE:FRX) and Cronos Group (TSE:CRON) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, media sentiment, dividends and valuation.

12.7% of Fennec Pharmaceuticals shares are held by institutional investors. Comparatively, 4.6% of Cronos Group shares are held by institutional investors. 16.2% of Fennec Pharmaceuticals shares are held by company insiders. Comparatively, 46.4% of Cronos Group shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Cronos Group has a consensus target price of C$4.75, indicating a potential upside of 26.33%. Given Cronos Group's higher probable upside, analysts plainly believe Cronos Group is more favorable than Fennec Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fennec Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	4.00
Cronos Group	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Cronos Group has a net margin of -1.29% compared to Fennec Pharmaceuticals' net margin of -17.22%. Cronos Group's return on equity of -0.19% beat Fennec Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fennec Pharmaceuticals	-17.22%	-58.09%	8.88%
Cronos Group	-1.29%	-0.19%	-3.73%

Fennec Pharmaceuticals has a beta of 3.518081, meaning that its share price is 252% more volatile than the broader market. Comparatively, Cronos Group has a beta of 1.134248, meaning that its share price is 13% more volatile than the broader market.

In the previous week, Fennec Pharmaceuticals had 4 more articles in the media than Cronos Group. MarketBeat recorded 4 mentions for Fennec Pharmaceuticals and 0 mentions for Cronos Group. Fennec Pharmaceuticals' average media sentiment score of 0.20 beat Cronos Group's score of 0.00 indicating that Fennec Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Fennec Pharmaceuticals	Neutral
Cronos Group	Neutral

Fennec Pharmaceuticals has higher earnings, but lower revenue than Cronos Group.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fennec Pharmaceuticals	C$51.00M	8.45	-C$800.44K	-C$0.29	N/A
Cronos Group	C$159.54M	8.81	-C$32.78M	N/A	N/A

Summary

Fennec Pharmaceuticals beats Cronos Group on 9 of the 16 factors compared between the two stocks.

How does Fennec Pharmaceuticals compare to Tilray Brands?

Tilray Brands (TSE:TLRY) and Fennec Pharmaceuticals (TSE:FRX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, dividends, risk, valuation, analyst recommendations, institutional ownership and media sentiment.

Tilray Brands has a beta of 3.007995, meaning that its stock price is 201% more volatile than the broader market. Comparatively, Fennec Pharmaceuticals has a beta of 3.518081, meaning that its stock price is 252% more volatile than the broader market.

4.4% of Tilray Brands shares are held by institutional investors. Comparatively, 12.7% of Fennec Pharmaceuticals shares are held by institutional investors. 0.7% of Tilray Brands shares are held by company insiders. Comparatively, 16.2% of Fennec Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Fennec Pharmaceuticals has a net margin of -17.22% compared to Tilray Brands' net margin of -158.75%. Fennec Pharmaceuticals' return on equity of -58.09% beat Tilray Brands' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tilray Brands	-158.75%	-88.06%	-1.41%
Fennec Pharmaceuticals	-17.22%	-58.09%	8.88%

Tilray Brands presently has a consensus target price of C$13.30, suggesting a potential upside of 91.09%. Given Tilray Brands' higher possible upside, analysts plainly believe Tilray Brands is more favorable than Fennec Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tilray Brands	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Fennec Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	4.00

In the previous week, Fennec Pharmaceuticals had 2 more articles in the media than Tilray Brands. MarketBeat recorded 4 mentions for Fennec Pharmaceuticals and 2 mentions for Tilray Brands. Fennec Pharmaceuticals' average media sentiment score of 0.20 beat Tilray Brands' score of 0.07 indicating that Fennec Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tilray Brands	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Fennec Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Fennec Pharmaceuticals has lower revenue, but higher earnings than Tilray Brands. Fennec Pharmaceuticals is trading at a lower price-to-earnings ratio than Tilray Brands, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tilray Brands	C$858.28M	0.98	-C$183.24M	-C$14.63	N/A
Fennec Pharmaceuticals	C$51.00M	8.45	-C$800.44K	-C$0.29	N/A

Summary

Fennec Pharmaceuticals beats Tilray Brands on 13 of the 16 factors compared between the two stocks.

How does Fennec Pharmaceuticals compare to International Tower Hill Mines?

Fennec Pharmaceuticals (TSE:FRX) and International Tower Hill Mines (TSE:ITH) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, risk, dividends, profitability, analyst recommendations, earnings and valuation.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fennec Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	4.00
International Tower Hill Mines	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Fennec Pharmaceuticals has a beta of 3.518081, meaning that its share price is 252% more volatile than the broader market. Comparatively, International Tower Hill Mines has a beta of 2.117403, meaning that its share price is 112% more volatile than the broader market.

12.7% of Fennec Pharmaceuticals shares are owned by institutional investors. Comparatively, 9.1% of International Tower Hill Mines shares are owned by institutional investors. 16.2% of Fennec Pharmaceuticals shares are owned by company insiders. Comparatively, 0.5% of International Tower Hill Mines shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Fennec Pharmaceuticals has higher revenue and earnings than International Tower Hill Mines. International Tower Hill Mines is trading at a lower price-to-earnings ratio than Fennec Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fennec Pharmaceuticals	C$51.00M	8.45	-C$800.44K	-C$0.29	N/A
International Tower Hill Mines	N/A	N/A	-C$2.36M	-C$0.01	N/A

International Tower Hill Mines has a net margin of 0.00% compared to Fennec Pharmaceuticals' net margin of -17.22%. International Tower Hill Mines' return on equity of -2.04% beat Fennec Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fennec Pharmaceuticals	-17.22%	-58.09%	8.88%
International Tower Hill Mines	N/A	-2.04%	-3.65%

In the previous week, Fennec Pharmaceuticals had 4 more articles in the media than International Tower Hill Mines. MarketBeat recorded 4 mentions for Fennec Pharmaceuticals and 0 mentions for International Tower Hill Mines. Fennec Pharmaceuticals' average media sentiment score of 0.20 beat International Tower Hill Mines' score of 0.00 indicating that Fennec Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Fennec Pharmaceuticals	Neutral
International Tower Hill Mines	Neutral

Summary

Fennec Pharmaceuticals beats International Tower Hill Mines on 11 of the 14 factors compared between the two stocks.

How does Fennec Pharmaceuticals compare to Tervita?

Tervita (TSE:TEV) and Fennec Pharmaceuticals (TSE:FRX) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, earnings, risk, media sentiment, valuation, analyst recommendations and institutional ownership.

Fennec Pharmaceuticals has lower revenue, but higher earnings than Tervita. Fennec Pharmaceuticals is trading at a lower price-to-earnings ratio than Tervita, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tervita	C$1.36B	0.00	-C$1.04M	-C$0.01	N/A
Fennec Pharmaceuticals	C$51.00M	8.45	-C$800.44K	-C$0.29	N/A

In the previous week, Fennec Pharmaceuticals had 4 more articles in the media than Tervita. MarketBeat recorded 4 mentions for Fennec Pharmaceuticals and 0 mentions for Tervita. Fennec Pharmaceuticals' average media sentiment score of 0.20 beat Tervita's score of 0.00 indicating that Fennec Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Tervita	Neutral
Fennec Pharmaceuticals	Neutral

Tervita has a net margin of 0.00% compared to Fennec Pharmaceuticals' net margin of -17.22%. Tervita's return on equity of 0.00% beat Fennec Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tervita	N/A	N/A	N/A
Fennec Pharmaceuticals	-17.22%	-58.09%	8.88%

Given Tervita's higher possible upside, equities research analysts plainly believe Tervita is more favorable than Fennec Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tervita	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Fennec Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	4.00

12.7% of Fennec Pharmaceuticals shares are held by institutional investors. 16.2% of Fennec Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Fennec Pharmaceuticals beats Tervita on 9 of the 14 factors compared between the two stocks.

Get Fennec Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FRX vs. The Competition

Export

Metric	Fennec Pharmaceuticals	Biotechnology Industry	Medical Sector	TSE Exchange
Market Cap	C$430.74M	C$379.02M	C$6.74B	C$13.03B
Dividend Yield	2.02%	3.88%	2.67%	6.19%
P/E Ratio	-42.76	3.11	24.21	36.94
Price / Sales	8.45	6,480.47	512.04	10.45
Price / Cash	11.66	13.13	27.48	82.29
Price / Book	11.33	89.03	10.66	4.47
Net Income	-C$800.44K	-C$96.07M	C$3.57B	C$299.09M
7 Day Performance	N/A	-0.96%	0.84%	0.89%
1 Month Performance	-1.98%	-0.46%	-0.34%	-1.07%
1 Year Performance	15.24%	56.16%	25.40%	41.92%

Fennec Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count
FRX Fennec Pharmaceuticals	0.153 of 5 stars	C$12.40 flat	N/A	N/A	C$430.74M	C$51.00M	N/A	10
CARA Cara Operations	N/A	N/A	N/A	N/A	C$1.62B	N/A	N/A	80
CRON Cronos Group	2.0409 of 5 stars	C$3.76 -2.6%	C$4.75 +26.3%	+43.0%	C$1.40B	C$159.54M	N/A	450
TLRY Tilray Brands	1.3647 of 5 stars	C$6.96 -2.4%	C$13.30 +91.1%	+24.3%	C$840.89M	C$858.28M	N/A	2,650
ITH International Tower Hill Mines	N/A	C$2.96 +3.1%	N/A	+133.1%	C$774.45M	N/A	N/A	220

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (TSE:FRX) was last updated on 6/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Fennec Pharmaceuticals (FRX) Competitors

FRX vs. CARA, CRON, TLRY, ITH, and TEV

How does Fennec Pharmaceuticals compare to Cara Operations?

Summary

How does Fennec Pharmaceuticals compare to Cronos Group?

Summary

How does Fennec Pharmaceuticals compare to Tilray Brands?

Summary

How does Fennec Pharmaceuticals compare to International Tower Hill Mines?

Summary

How does Fennec Pharmaceuticals compare to Tervita?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FRX vs. The Competition

Fennec Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Fennec Pharmaceuticals (FRX) Competitors

FRX vs. CARA, CRON, TLRY, ITH, and TEV

How does Fennec Pharmaceuticals compare to Cara Operations?

Which has higher valuation & earnings, CARA or FRX?

Do institutionals & insiders believe in CARA or FRX?

Is CARA or FRX more profitable?

Does the media favor CARA or FRX?

Do analysts prefer CARA or FRX?

Summary

How does Fennec Pharmaceuticals compare to Cronos Group?

Do insiders and institutionals believe in FRX or CRON?

Do analysts rate FRX or CRON?

Is FRX or CRON more profitable?

Which has more volatility and risk, FRX or CRON?

Does the media refer more to FRX or CRON?

Which has stronger valuation and earnings, FRX or CRON?

Summary

How does Fennec Pharmaceuticals compare to Tilray Brands?

Which has more risk & volatility, TLRY or FRX?

Do insiders and institutionals hold more shares of TLRY or FRX?

Is TLRY or FRX more profitable?

Do analysts prefer TLRY or FRX?

Does the media prefer TLRY or FRX?

Which has stronger earnings and valuation, TLRY or FRX?

Summary

How does Fennec Pharmaceuticals compare to International Tower Hill Mines?

Do analysts rate FRX or ITH?

Which has more risk & volatility, FRX or ITH?

Do institutionals & insiders hold more shares of FRX or ITH?

Which has stronger valuation & earnings, FRX or ITH?

Is FRX or ITH more profitable?

Does the media refer more to FRX or ITH?

Summary

How does Fennec Pharmaceuticals compare to Tervita?

Which has preferable valuation & earnings, TEV or FRX?

Does the media prefer TEV or FRX?

Is TEV or FRX more profitable?

Do analysts prefer TEV or FRX?

Do insiders and institutionals hold more shares of TEV or FRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FRX vs. The Competition

Fennec Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools